Aducanumab Continues to Show Potential as Treatment for Mild Alzheimer’s in Long-term Extension of PRIME Trial

Aducanumab Continues to Show Potential as Treatment for Mild Alzheimer’s in Long-term Extension of PRIME Trial
Latest results from the long-term extension of a Phase 1b study assessing increasing and fixed doses of aducanumab continue to show its potential as a therapy for early or mild Alzheimer’s disease. Similar to previous interim analyses, data collected for up to 48 months reveal that the investigative treatment can effectively reduce the burden of amyloid plaques — a hallmark of the disease – and prevent cognitive decline in Alzheimer’s patients. Aducanumab, formerly known as BIIB037, is a monoclonal antibody being developed by Biogen in collaboration with Eisai. Prior preclinical and clinical data suggest that aducanumab’s therapeutic potential resides in its ability to target disease-causing amyloid protein clusters. The ongoing PRIME trial (NCT01677572) is evaluating the safety, tolerability, and overall reactivity of aducanumab in patients with prodromal (early) or mild Alzheimer’s disease dementia. A total of 196 participants, ages 50 to 90, were enrolled across some 30 research centers in the United States. They were randomized to receive either a fixed dose of aducanumab or placebo — 1, 3, 6, or 10 mg/kg — or to undergo a titration regimen in which they received a gradually increasing dose of the antibody or place
Subscribe or to access all post and page content.